Business Description
Nurix Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US67080M1036
Share Class Description:
NRIX: Ordinary SharesDescription
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 16.51 | |||||
| Equity-to-Asset | 0.73 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -0.15 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 4.37 | |||||
| Beneish M-Score | -4.5 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7.6 | |||||
| 3-Year EBITDA Growth Rate | 13.4 | |||||
| 3-Year EPS without NRI Growth Rate | 1.3 | |||||
| 3-Year FCF Growth Rate | -77.4 | |||||
| 3-Year Book Growth Rate | -18 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -4.49 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.34 | |||||
| 9-Day RSI | 37.76 | |||||
| 14-Day RSI | 38.92 | |||||
| 3-1 Month Momentum % | 9.48 | |||||
| 6-1 Month Momentum % | 62.28 | |||||
| 12-1 Month Momentum % | 222.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.28 | |||||
| Quick Ratio | 5.28 | |||||
| Cash Ratio | 5.19 | |||||
| Days Sales Outstanding | 12.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.8 | |||||
| Shareholder Yield % | -1.3 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -343.3 | |||||
| Net Margin % | -313.65 | |||||
| FCF Margin % | -189.45 | |||||
| ROE % | -65.52 | |||||
| ROA % | -44.22 | |||||
| ROIC % | -160.45 | |||||
| 3-Year ROIIC % | 2056.78 | |||||
| ROC (Joel Greenblatt) % | -456.26 | |||||
| ROCE % | -60.61 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 22.08 | |||||
| PB Ratio | 3.61 | |||||
| Price-to-Tangible-Book | 3.61 | |||||
| EV-to-EBIT | -5.35 | |||||
| EV-to-Forward-EBIT | -3.78 | |||||
| EV-to-EBITDA | -5.82 | |||||
| EV-to-Forward-EBITDA | -3.9 | |||||
| EV-to-Revenue | 18.35 | |||||
| EV-to-Forward-Revenue | 18.42 | |||||
| EV-to-FCF | -9.69 | |||||
| Price-to-GF-Value | 2.06 | |||||
| Price-to-Net-Current-Asset-Value | 4.26 | |||||
| Price-to-Net-Cash | 4.37 | |||||
| Earnings Yield (Greenblatt) % | -18.69 | |||||
| FCF Yield % | -7.44 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NRIX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nurix Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 56.424 | ||
| EPS (TTM) ($) | -2.91 | ||
| Beta | 2.01 | ||
| 3-Year Sharpe Ratio | 0.18 | ||
| 3-Year Sortino Ratio | 0.32 | ||
| Volatility % | 98.46 | ||
| 14-Day RSI | 38.92 | ||
| 14-Day ATR ($) | 1.478362 | ||
| 20-Day SMA ($) | 21.55 | ||
| 12-1 Month Momentum % | 222.83 | ||
| 52-Week Range ($) | 7.65 - 29.56 | ||
| Shares Outstanding (Mil) | 70.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nurix Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nurix Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Nurix Therapeutics Inc Frequently Asked Questions
What is Nurix Therapeutics Inc(NRIX)'s stock price today?
The current price of NRIX is $20.27. The 52 week high of NRIX is $29.56 and 52 week low is $7.65.
When is next earnings date of Nurix Therapeutics Inc(NRIX)?
The next earnings date of Nurix Therapeutics Inc(NRIX) is 2025-02-14 Est..
Does Nurix Therapeutics Inc(NRIX) pay dividends? If so, how much?
Nurix Therapeutics Inc(NRIX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers